• Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$74.63
▲ +0.86 (1.17%)

This chart shows the closing price for UCBJY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New UCB Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UCBJY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UCBJY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for UCB in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $74.63.

This chart shows the closing price for UCBJY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in UCB. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/26/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
5/31/2023UBS GroupInitiated CoverageBuy
6/27/2022Societe GeneraleLower TargetBuy ➝ Buy€111.00 ➝ €106.00
6/27/2022UBS GroupLower TargetNeutral ➝ Neutral€95.00 ➝ €87.00
6/7/2022Deutsche Bank AktiengesellschaftLower Target€95.00 ➝ €90.00
5/20/2022Berenberg BankLower TargetBuy ➝ Buy€122.00 ➝ €120.00
5/19/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
3/3/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight
1/24/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
1/13/2022UBS GroupDowngradeBuy ➝ Sell
1/10/2022CitigroupDowngradeBuy ➝ Neutral
10/19/2021BarclaysDowngradeOverweight ➝ Equal Weight
9/16/2021Jefferies Financial GroupUpgradeHold ➝ Buy
9/2/2021BarclaysReiterated RatingOverweight
9/2/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
8/23/2021UBS GroupUpgradeNeutral ➝ Buy
7/23/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$52.84
7/14/2021BarclaysReiterated RatingOverweight
7/12/2021Exane BNP ParibasUpgradeNeutral ➝ Outperform
7/9/2021Societe GeneraleInitiated CoverageBuy
4/26/2021Morgan StanleyReiterated RatingEqual Weight
3/5/2021Morgan StanleyInitiated CoverageEqual Weight
3/3/2021UBS GroupReiterated RatingNeutral
1/22/2021BarclaysReiterated RatingOverweight
1/4/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
11/25/2020UBS GroupReiterated RatingNeutral
7/31/2020UBS GroupDowngradeBuy ➝ Neutral
7/28/2020JPMorgan Chase & Co.Reiterated RatingOverweight
1/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
10/29/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
9/5/2019BarclaysUpgradeUnderweight ➝ Equal Weight
(Data available from 6/19/2019 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
UCB logo
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Read More

Today's Range

Now: $74.63
Low: $74.25
High: $74.63

50 Day Range

MA: $67.43
Low: $61.79
High: $74.63

52 Week Range

Now: $74.63
Low: $34.85
High: $74.63

Volume

18,605 shs

Average Volume

18,218 shs

Market Capitalization

N/A

P/E Ratio

97.76

Dividend Yield

1.26%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of UCB?

The following Wall Street research analysts have issued research reports on UCB in the last twelve months: Jefferies Financial Group Inc..
View the latest analyst ratings for UCBJY.

What is the current price target for UCB?

0 Wall Street analysts have set twelve-month price targets for UCB in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for UCB in the next year.
View the latest price targets for UCBJY.

What is the current consensus analyst rating for UCB?

UCB currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in UCBJY, but not buy more shares or sell existing shares.
View the latest ratings for UCBJY.

What other companies compete with UCB?

How do I contact UCB's investor relations team?

UCB's physical mailing address is Allee de la Recherche, 60, Anderlecht, Bruxelles Capitale 1070. The company's listed phone number is (322) 559-9999. The official website for UCB is www.ucb.com. Learn More about contacing UCB investor relations.